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Kucukseymen et al 1 consider some interesting points regarding inflammation, the atherosclerotic process, and arterial disease. They question which process comes first.
A number of observational and interventional studies have demonstrated the role of inflammation in peripheral arterial disease (PAD).
1,2 I agree with the suggestion that C-reactive protein (CRP) should be considered a useful marker of inflammation.
1 However, in patients screened for unrecognized PAD, we demonstrated high levels of chemokines and selectins, but they had a low level of transforming growth factor b-1. 3 We postulate a pivotal role of diverse mechanisms (pro-inflammatory and immunological) that play a role in the initiation and progression of PAD. Other studies 2 have demonstrated the association between increased circulating levels of several biomarkers with the presence of the PAD, 4 its severity, 5 and clinical outcomes. 6 Furthermore, studies have shown that therapeutic challenges (ie, propionyl-L-carnitine, sulodexide, and statins) 7-12 and physical training 13 are effective in reducing the circulating plasma levels of several inflammatory biomarkers.
In conclusion, it is important to consider CRP a marker of inflammation. On the other hand, we need to focus on several biomarkers 14 to elucidate the multiple facets of the inflammatory pathways. 
